Hereditary hemochromatosis affects ~1 in 200 people of Northern European descent. Yet 𝘏𝘍𝘌 research testing remains underutilized...
More
Jai Patel, PharmD
Associate Vice President, Translational Research; Director of Cancer Pharmacology & Pharmacogenomics; Associate Professor, Cancer Biology
Dr. Patel is the Associate Vice President of Translational Research and Director of Cancer Pharmacology & Pharmacogenomics at Atrium Health Levine Cancer and Associate Director for Shared Resources Management at Atrium Health Wake Forest Baptist Comprehensive Cancer Center. He is also Associate Professor in the Department of Cancer Biology at the Wake Forest University School of Medicine.
Dr. Patel received his Doctorate in Pharmacy from the University of North Carolina Eshelman School of Pharmacy and completed an oncology pharmacogenomics postdoctoral fellowship at the UNC Center for Pharmacogenomics and Individualized Therapy. Dr. Patel leads translational and clinical pharmacology research at the cancer center, with an emphasis on pharmacogenomics research and implementation, and oversees pharmacogenomics integration across the health enterprise. Dr. Patel has published over 170 articles, editorials, book chapters, and abstracts on the topics of pharmacogenomics, pharmacology, and pharmaceutical sciences.
Victoria M. Pratt, PhD, FACMG
Director of Scientific Affairs for Pharmacogenetics, Agena Bioscience
Dr. Pratt is the Past President of the Association for Molecular Pathology and continues to serve on the Centers for Disease Control and Prevention (CDC) GeT-RM Genetic Testing Reference Materials Program, the National Academy of Medicine’s Roundtable on Genomics and Precision Health, and the American Medical Association’s (AMA) Molecular Pathology Current Procedural Terminology (CPT) Advisory Committee.
Dr. Pratt earned her Ph.D. in Medical and Molecular Genetics from Indiana University School of Medicine and completed fellowship training in Medical and Clinical Molecular Genetics at Henry Ford Hospital in Detroit, MI.
Jai Patel, PharmD
Associate Vice President, Translational Research; Director of Cancer Pharmacology & Pharmacogenomics; Associate Professor, Cancer Biology
Dr. Patel is the Associate Vice President of Translational Research and Director of Cancer Pharmacology & Pharmacogenomics at Atrium Health Levine Cancer and Associate Director for Shared Resources Management at Atrium Health Wake Forest Baptist Comprehensive Cancer Center. He is also Associate Professor in the Department of Cancer Biology at the Wake Forest University School of Medicine.
Dr. Patel received his Doctorate in Pharmacy from the University of North Carolina Eshelman School of Pharmacy and completed an oncology pharmacogenomics postdoctoral fellowship at the UNC Center for Pharmacogenomics and Individualized Therapy. Dr. Patel leads translational and clinical pharmacology research at the cancer center, with an emphasis on pharmacogenomics research and implementation, and oversees pharmacogenomics integration across the health enterprise. Dr. Patel has published over 170 articles, editorials, book chapters, and abstracts on the topics of pharmacogenomics, pharmacology, and pharmaceutical sciences.
Laila Mnayer, MS, PhD, ABMGG, FACMG
Division Director, Molecular Pathology and Cytogenetics
Dr. Mnayer’s experience in clinical genetics and cytogenetics spans over 25 years. She trained initially in cytogenetics and oncology at The Royal Free Hospital in England as the recipient of a United Nations fellowship, then studied clinical cytogenetics at Georgetown University Hospital as a WHO fellow. Dr. Mnayer subsequently obtained her PhD in Biochemistry and Molecular Genetics at the University of Miami and completed a three-year postdoctoral fellowship in clinical molecular genetics at the McDonald’s Foundation for Medical Genetics – Miller School of Medicine at the University of Miami. She also completed a two-year postdoctoral fellowship in clinical cytogenetics at Tufts New England Medical Center and has received dual certification by the American College of Medical Genetics and Genomics in Clinical Molecular Genetics and Clinical Cytogenetics.
Dr. Mnayer has directed the Molecular Pathology and Cytogenetics Laboratories at Hartford Hospital since 2006 and has introduced myriad clinical assays and testing platforms during that time. She established clinical cytogenetics services in 2008 and subsequently introduced cytogenomic microarrays for the diagnosis of congenital abnormalities and tumor profiling. In 2017, Dr. Mnayer launched next-generation sequencing (NGS) for solid tumors and leukemias / lymphomas. More recently, she expanded the NGS panels to incorporate newer molecular substrates for targeted therapies and introduced multiple Rapid Molecular Panels running on the MassARRAY® System for the timely identification of biomarkers essential for targeted therapy in lung cancer, acute myeloid leukemia, and others.
Dr. Mnayer’s team includes technologists and specialists in bioinformatics, information technology, and administration. She collaborates closely with colleagues in Pathology & Laboratory Medicine and with oncologists who rely on her laboratory’s work to ensure Hartford Hospital remains at the cutting edge of molecular diagnostics. She also participates in tumor boards and disease management teams, including intercity heme-oncology, breast, thoracic, and gynecology.
Dr. Mnayer is a Fellow of the American College of Medical Genetics and Genomics (ACMGG), a member of the Association for Molecular Pathology (AMP), the International Association for the Study of Lung Cancer (IASLC), the Children’s Oncology Group (COG), and the American Cytogenetics Conference (ACC), and a member of the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
Dr. Mnayer also serves on the advisory boards of Bristol Myers Squibb (BMS), Eli Lilly, Novartis, Personal Genome Diagnostics (PGDx), and Asuragen.
